Artemether Alleviates Diabetic Kidney Disease by Modulating Amino Acid Metabolism
| Autor: | Guangli Rong, Wenci Weng, Jingting Huang, Yijun Chen, Xuewen Yu, Rui Yuan, Xiufen Gu, Xia Wu, Yuchun Cai, Pengxun Han, Mumin Shao, Huili Sun, Na Ge |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
General Immunology and Microbiology
endocrine system diseases Article Subject nutritional and metabolic diseases General Medicine Kidney General Biochemistry Genetics and Molecular Biology Diabetes Mellitus Experimental Mice Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Tandem Mass Spectrometry Animals Humans Diabetic Nephropathies Artemether Amino Acids Chromatography Liquid |
| Zdroj: | BioMed Research International. |
| ISSN: | 2314-6133 |
| DOI: | 10.1155/2022/7339611 |
| Popis: | Diabetes is a worldwide metabolic disease with rapid growing incidence, characterized by hyperglycemia. Diabetic kidney disease (DKD), the leading cause of chronic kidney disease (CKD), has a high morbidity according to the constantly increasing diabetic patients and always develops irreversible deterioration of renal function. Though different in pathogenesis, clinical manifestations, and therapies, both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) can evolve into DKD. Since amino acids are both biomarkers and causal agents, rarely report has been made about its metabolism which lies in T1DM- and T2DM-related kidney disease. This study was designed to investigate artemether in adjusting renal amino acid metabolism in T1DM and T2DM mice. Artemether was applied as treatment in streptozotocin (STZ) induced T1DM mice and db/db T2DM mice, respectively. Artemether-treated mice showed lower FBG and HbA1c and reduced urinary albumin excretion, as well as urinary NAG. Both types of diabetic mice showed enlarged kidneys, as confirmed by increased kidney weight and the ratio of kidney weight to body weight. Artemether normalized kidney size and thus attenuated renal hypertrophy. Kidney tissue UPLC-MS analysis showed that branched-chain amino acids (BCAAs) and citrulline were upregulated in diabetic mice without treatment and downregulated after being treated with artemether. Expressions of glutamine, glutamic acid, aspartic acid, ornithine, glycine, histidine, phenylalanine and threonine were decreased in both types of diabetic mice whereas they increased after artemether treatment. The study demonstrates the initial evidence that artemether exerted renal protection in DKD by modulating amino acid metabolism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |